94,820 Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Carnegie Lake Advisors LLC

Carnegie Lake Advisors LLC cut its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 96.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,080 shares of the company’s stock after selling 94,820 shares during the period. Carnegie Lake Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $122,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. M Holdings Securities Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $637,000. Brighton Jones LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $227,000. Ethic Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 63.7% during the 3rd quarter. Ethic Inc. now owns 33,024 shares of the company’s stock worth $1,308,000 after purchasing an additional 12,853 shares during the period. Parallel Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 8.7% during the 3rd quarter. Parallel Advisors LLC now owns 4,626 shares of the company’s stock worth $183,000 after purchasing an additional 370 shares during the period. Finally, Kestra Advisory Services LLC increased its position in Teva Pharmaceutical Industries by 16.6% during the 3rd quarter. Kestra Advisory Services LLC now owns 53,716 shares of the company’s stock worth $2,127,000 after purchasing an additional 7,631 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEVA has been the topic of several research reports. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Leerink Partners boosted their price objective on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday. TD Cowen boosted their price objective on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Finally, Zacks Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $47.23.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva’s third-quarter earnings beat estimates, and the company raised its 2026 revenue and product-sales outlook, citing strong branded-drug sales. Revenue was slightly lower year over year, but the results and upgraded outlook were encouraging. Article: Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: A report highlighted 33% sales growth last quarter across Teva’s three key branded medicines, alongside improved margins and net-debt reduction—factors that could strengthen earnings and the balance sheet. Article: Teva’s 3 Key Branded Drugs Grew Sales 33% Last Quarter
• Positive Sentiment: Leerink Partners raised its price target to $52 from $45 and maintained an “outperform” rating, signaling greater analyst confidence in potential upside. Article: Leerink Partners Raises Teva Price Target
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $52 target and projected 2027 EPS of $3.03, well above its 2026 estimate of $1.94. Teva analyst estimates
• Negative Sentiment: Insider Mark Sabag sold 46,000 shares for about $1.93 million, reducing his direct holdings by 36.29%. Insider sales can weigh on sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC insider transaction filing

Insider Activity

In related news, insider Mark Sabag sold 46,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $3,386,266.80. The trade was a 36.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares of the company’s stock, valued at approximately $330,225. This represents a 46.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 420,942 shares of company stock worth $16,572,473. 0.54% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Trading Down 0.2%

NYSE:TEVA opened at $42.52 on Monday. The business’s 50-day moving average is $39.49 and its two-hundred day moving average is $34.79. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. Teva Pharmaceutical Industries Ltd. has a 12 month low of $23.61 and a 12 month high of $43.34. The firm has a market capitalization of $49.55 billion, a PE ratio of 98.88, a price-to-earnings-growth ratio of 4.00 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the previous year, the firm posted $0.78 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. Research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas.

Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Teva is headquartered in Tel Aviv, Israel.